Neoadjuvant Pyrotinib-to-pertuzumab in HER2+ eBC
Neoadjuvant Pyrotinib-to-pertuzumab in HER2+ eBC
Recruiting · NCT07797218 · Registry updated 2026-09-01Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Neoadjuvant Pyrotinib-to-pertuzumab in HER2+ eBC | Neoplasms by Site, Skin and Connective Tissue Diseases, breast disorder, breast neoplasm, neoplasm, skin disorder | Recruiting | Phase 3 | 2026-09-01 | NCT07797218 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Shanghai Jiao Tong University School of Medicine | 117 |
1 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Ruijin Hospital | Shanghai | China | 21 |